77 related articles for article (PubMed ID: 16501602)
1. GC-selective DNA-binding antibiotic, mithramycin A, reveals multiple points of control in the regulation of Hdm2 protein synthesis.
Phillips A; Darley M; Blaydes JP
Oncogene; 2006 Jul; 25(30):4183-93. PubMed ID: 16501602
[TBL] [Abstract][Full Text] [Related]
2. MNK1 and EIF4E are downstream effectors of MEKs in the regulation of the nuclear export of HDM2 mRNA.
Phillips A; Blaydes JP
Oncogene; 2008 Mar; 27(11):1645-9. PubMed ID: 17828301
[TBL] [Abstract][Full Text] [Related]
3. p53-independent activation of the hdm2-P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor alpha-positive breast cancer cells.
Phelps M; Darley M; Primrose JN; Blaydes JP
Cancer Res; 2003 May; 63(10):2616-23. PubMed ID: 12750288
[TBL] [Abstract][Full Text] [Related]
4. MEK-ERK signaling controls Hdm2 oncoprotein expression by regulating hdm2 mRNA export to the cytoplasm.
Phelps M; Phillips A; Darley M; Blaydes JP
J Biol Chem; 2005 Apr; 280(17):16651-8. PubMed ID: 15723837
[TBL] [Abstract][Full Text] [Related]
5. Low-dose mithramycin exerts its anticancer effect via the p53 signaling pathway and synergizes with nutlin-3 in gynecologic cancers.
Ohgami T; Kato K; Kobayashi H; Sonoda K; Inoue T; Yamaguchi S; Yoneda T; Wake N
Cancer Sci; 2010 Jun; 101(6):1387-95. PubMed ID: 20331637
[TBL] [Abstract][Full Text] [Related]
6. Association of HDM2 transcript levels with age of onset and prognosis in soft tissue sarcomas.
Taubert H; Bartel F; Greither T; Bache M; Kappler M; Köhler T; Böhnke A; Lautenschläger C; Schmidt H; Holzhausen HJ; Hauptmann S; Würl P
Mol Cancer Res; 2008 Oct; 6(10):1575-81. PubMed ID: 18922973
[TBL] [Abstract][Full Text] [Related]
7. Hodgkin's lymphoma cells express alternatively spliced forms of HDM2 with multiple effects on cell cycle control.
Sánchez-Aguilera A; García JF; Sánchez-Beato M; Piris MA
Oncogene; 2006 Apr; 25(18):2565-74. PubMed ID: 16331255
[TBL] [Abstract][Full Text] [Related]
8. Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein.
Roth J; Dobbelstein M; Freedman DA; Shenk T; Levine AJ
EMBO J; 1998 Jan; 17(2):554-64. PubMed ID: 9430646
[TBL] [Abstract][Full Text] [Related]
9. Detection of HDM2 and VEGF co-expression in cancer cell lines: novel effect of HDM2 antisense treatment on VEGF expression.
Narasimhan M; Rose R; Karthikeyan M; Rathinavelu A
Life Sci; 2007 Oct; 81(17-18):1362-72. PubMed ID: 17931661
[TBL] [Abstract][Full Text] [Related]
10. Interferon-inducible protein IFIXalpha1 functions as a negative regulator of HDM2.
Ding Y; Lee JF; Lu H; Lee MH; Yan DH
Mol Cell Biol; 2006 Mar; 26(5):1979-96. PubMed ID: 16479015
[TBL] [Abstract][Full Text] [Related]
11. Nuclear and cytoplasmic degradation of endogenous p53 and HDM2 occurs during down-regulation of the p53 response after multiple types of DNA damage.
Joseph TW; Zaika A; Moll UM
FASEB J; 2003 Sep; 17(12):1622-30. PubMed ID: 12958168
[TBL] [Abstract][Full Text] [Related]
12. An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2.
Evans SC; Viswanathan M; Grier JD; Narayana M; El-Naggar AK; Lozano G
Oncogene; 2001 Jul; 20(30):4041-9. PubMed ID: 11494132
[TBL] [Abstract][Full Text] [Related]
13. An intact HDM2 RING-finger domain is required for nuclear exclusion of p53.
Boyd SD; Tsai KY; Jacks T
Nat Cell Biol; 2000 Sep; 2(9):563-8. PubMed ID: 10980695
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of c-src transcription by mithramycin: structure-activity relationships of biosynthetically produced mithramycin analogues using the c-src promoter as target.
Remsing LL; Bahadori HR; Carbone GM; McGuffie EM; Catapano CV; Rohr J
Biochemistry; 2003 Jul; 42(27):8313-24. PubMed ID: 12846580
[TBL] [Abstract][Full Text] [Related]
15. Characterisation of a novel p53 down-regulated promoter in intron 3 of the human MDM2 oncogene.
Liang H; Lunec J
Gene; 2005 Nov; 361():112-8. PubMed ID: 16202543
[TBL] [Abstract][Full Text] [Related]
16. The oncoprotein SS18-SSX1 promotes p53 ubiquitination and degradation by enhancing HDM2 stability.
D'Arcy P; Maruwge W; Ryan BA; Brodin B
Mol Cancer Res; 2008 Jan; 6(1):127-38. PubMed ID: 18234968
[TBL] [Abstract][Full Text] [Related]
17. Consequences of the inhibition of Hdm2 expression in human osteosarcoma cells using antisense oligonucleotides.
Geiger T; Hüsken D; Weiler J; Natt F; Woods-Cook KA; Hall J; Fabbro D
Anticancer Drug Des; 2000 Dec; 15(6):423-30. PubMed ID: 11716435
[TBL] [Abstract][Full Text] [Related]
18. Mithramycin blocks transcriptional initiation of the c-myc P1 and P2 promoters.
Snyder RC; Ray R; Blume S; Miller DM
Biochemistry; 1991 Apr; 30(17):4290-7. PubMed ID: 1827033
[TBL] [Abstract][Full Text] [Related]
19. Regulation of hdm2 by stress-induced hdm2alt1 in tumor and nontumorigenic cell lines correlating with p53 stability.
Dias CS; Liu Y; Yau A; Westrick L; Evans SC
Cancer Res; 2006 Oct; 66(19):9467-73. PubMed ID: 17018602
[TBL] [Abstract][Full Text] [Related]
20. TGF-beta1-induced expression of human Mdm2 correlates with late-stage metastatic breast cancer.
Araki S; Eitel JA; Batuello CN; Bijangi-Vishehsaraei K; Xie XJ; Danielpour D; Pollok KE; Boothman DA; Mayo LD
J Clin Invest; 2010 Jan; 120(1):290-302. PubMed ID: 19955655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
